The Wall Street Journal: Biogen shares rise after FDA fast-tracks Alzheimer’s treatment

Biogen Inc. said its investigational therapy for the early stage of Alzheimer’s disease was granted fast-track designation by the U.S. Food and Drug Administration, a designation intended to bring promising drugs for serious conditions to market faster.

The Cambridge, Mass., biotechnology company’s shares BIIB, +0.13% rose 1.3% to $310 in recent after-hours trading.

The drug — called aducanumab — is designed to help clear the brain of beta amyloid plaques, which many scientists say play a role in causing Alzheimer’s, a progressive, memory-destroying condition associated with older age.

The treatment is in late-stage clinical trials to assess the safety and effectiveness of the treatment in slowing cognitive decline in patients with early and mild forms of Alzheimer’s disease.

>>> Original Source <<<